Clinical Trials Logo

Abnormal Karyotype clinical trials

View clinical trials related to Abnormal Karyotype.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT01503502 Active, not recruiting - Clinical trials for Myelogenous Leukemia, Chronic

A Phase II Study of Flumatinib Versus Imatinib to Treat Philadelphia Chromosome Positive Chronic Myelogenous Leukemia

Start date: August 2011
Phase: Phase 2
Study type: Interventional

It is an open-label, randomized, multi-center study. The efficacy and safety of two flumatinib doses, 400 mg once daily and 600 mg once daily, will be compared with imatinib 400 mg once daily in newly diagnosed (within 6 months) patients with Philadelphia chromosome-positive (Ph+) Chronic Myelogenous Leukemia in the chronic phase (CML-CP).

NCT ID: NCT01221376 Active, not recruiting - Clinical trials for Chronic Myeloid Leukemia (CML) With Philadelphia Chromosome-positive (Ph+)

Phase II Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Chronic Myeloid Leukemia (CML) Philadelphia Chromosome-positive (Ph+)

Start date: February 2011
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the hematological, cytogenetic and molecular response to continuous-use of Imatinib in children with CML Ph+.

NCT ID: NCT00966810 Active, not recruiting - Clinical trials for Philadelphia Chromosome-positive Chronic Myelocytic Leukemia

Allogeneic Stem Cell Transplantation in CML With Partial T Cell Depletion

Start date: December 1999
Phase: Phase 2/Phase 3
Study type: Interventional

Allogeneic stem cell transplantation, the only known curative modality for CML, was abandoned in recent years for a very effective and much less toxic targeted therapy with the tyrosine kinase inhibitors (TKIs). However, approximately one third of patients still need another treatment including stem cell transplantation. The study protocol comprised a cohort of consecutive patients with CML who received allogeneic stem cell transplantation using partial T cell depletion, with no post-transplant GvHD prophylaxis. Forty consecutive patients with CML underwent allogeneic stem cell transplantation from a matched sibling using partial T cell depletion (TCD), in a single institution. Escalated dose of donor lymphocyte infusion (DLI) was given in case of either relapse or presence of minimal residual disease (MRD) as detected by cytogenetic or molecular analysis. The purpose of the study is to decrease transplant-related toxicity.